When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma.
作者信息
Yiğit Kaya Süreyya, Melek Elif, Mutlu Yaşa Gül, Beköz Hüseyin Saffet, Maral Senem, Kaynar Leylagül, Sevindik Ömür Gökmen
机构信息
Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
出版信息
Ann Hematol. 2025 Mar;104(3):2079-2080. doi: 10.1007/s00277-025-06285-2. Epub 2025 Feb 28.
Abstract
摘要
相似文献
1
When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma.当高剂量甲氨蝶呤不再起作用时，在一例继发性中枢神经系统淋巴瘤中，使用TEDDI-R成功过渡到移植。
Ann Hematol. 2025 Mar;104(3):2079-2080. doi: 10.1007/s00277-025-06285-2. Epub 2025 Feb 28.
2
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.利妥昔单抗治疗原发性中枢神经系统淋巴瘤（HOVON 105/ALLG NHL 24 研究）：一项随机、开放标签、III 期分组研究。
Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7.
3
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.鞘内注射利妥昔单抗、大剂量甲氨蝶呤以及R-DHAP方案序贯自体干细胞移植治疗继发性中枢神经系统淋巴瘤：HOVON 80二期研究结果
Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.
4
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.对于原发性中枢神经系统淋巴瘤患者，在对高剂量甲氨蝶呤为基础的化疗耐药或复发时，使用利妥昔单抗、异环磷酰胺和依托泊苷（R-IE 方案）进行挽救性化疗免疫治疗。
Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037. Epub 2012 Nov 14.
5
Successful Treatment of Central Nervous System Post-Transplant Lymphoproliferative Disease With a Reduced Dose of High-Dose Methotrexate.低剂量大剂量甲氨蝶呤成功治疗移植后中枢神经系统淋巴组织增生性疾病
Cureus. 2022 Dec 15;14(12):e32567. doi: 10.7759/cureus.32567. eCollection 2022 Dec.
6
Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review.异基因造血干细胞移植后中枢神经系统移植后淋巴细胞增殖性疾病经阿卡拉布替尼与免疫化疗联合治疗成功：一例报告及文献综述
EJHaem. 2024 Dec 28;6(1):e1078. doi: 10.1002/jha2.1078. eCollection 2025 Feb.
7
Characterizing second line and beyond therapies for primary central nervous system lymphomas.描述原发性中枢神经系统淋巴瘤的二线及以上治疗方法。
Hematol Oncol. 2024 Nov;42(6):e3313. doi: 10.1002/hon.3313.
8
Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.利妥昔单抗、替莫唑胺和大剂量甲氨蝶呤治疗中枢神经系统淋巴瘤且不进行巩固治疗的长期疗效。
Int J Hematol Oncol. 2017 Dec;6(4):113-121. doi: 10.2217/ijh-2017-0020. Epub 2018 Jan 26.
9
Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate.大剂量甲氨蝶呤成功治疗复发性原发性中枢神经系统淋巴瘤。
Cancer. 1980 Apr 1;45(7):1556-7. doi: 10.1002/1097-0142(19800401)45:7<1556::aid-cncr2820450707>3.0.co;2-b.
10
Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.比较不同剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤患者的疗效。
J Oncol Pharm Pract. 2024 Apr;30(3):513-518. doi: 10.1177/10781552231176754. Epub 2023 May 17.
本文引用的文献
1
SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.SOHO 最新进展及后续问题：中枢神经系统淋巴瘤的预防和治疗。
Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):709-717. doi: 10.1016/j.clml.2022.06.002. Epub 2022 Jun 6.
2
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.弥漫性大B细胞淋巴瘤中高剂量甲氨蝶呤中枢神经系统预防的时机：1384例患者的多中心国际分析
Blood. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506.
3
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.依鲁替尼对原发性中枢神经系统淋巴瘤中B细胞受体信号传导的抑制作用
Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.
Zotero 插件